SLC5A2 and hydrops fetalis: Our further analyses to determine the TTB at different clinically meaningful thresholds indicated that 0.19 (95% CI, 0.12-0.35) months were needed to prevent 1 HF hospitalization or CV death per 500 patients with the SGLT2 inhibitors treatment (ARR, 0.002).